Loading…
Significance of volume-reduction surgery for far-advanced gastric cancer during treatment with novel anticancer agents
Background We retrospectively assessed the survival benefit of novel anticancer agents (NACA) after volume-reduction surgery for far-advanced gastric cancer (FAGC). Methods From 1995 to 2005, 41 patients with FAGC underwent chemotherapy after volume-reduction surgery. Those treated since 2000 who re...
Saved in:
| Published in: | International journal of clinical oncology 2009-06, Vol.14 (3), p.225-229 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c405t-58f75aa42aeefa5d0e329cf0e75cfc88cadab1d7ee6cf824eb2b2d62bc766c493 |
| container_end_page | 229 |
| container_issue | 3 |
| container_start_page | 225 |
| container_title | International journal of clinical oncology |
| container_volume | 14 |
| creator | Yamamoto, Yuji Yoshikawa, Takaki Morinaga, Souichirou Kasahara, Akira Yoneyama, Katsuya Osaragi, Tomohiko Matsuura, Hitoshi Yoshida, Tatsuya Hasegawa, Shinichi |
| description | Background
We retrospectively assessed the survival benefit of novel anticancer agents (NACA) after volume-reduction surgery for far-advanced gastric cancer (FAGC).
Methods
From 1995 to 2005, 41 patients with FAGC underwent chemotherapy after volume-reduction surgery. Those treated since 2000 who received NACA were referred to as group A, and those treated before 2000, who received anticancer agents other than NACA, were referred to as group B. In addition, 21 patients with unresectable gastric cancer treated since 2000 who received NACA were referred to as group C. We investigated the significance of volume-reduction surgery during treatment with NACA.
Results
The median survival time (MST) was significantly prolonged in group A (626 days) compared to group B (364 days;
P
= 0.0156). Multivariate analysis showed that having one noncurative factor (NCF), and the use of NACA, were factors that contributed to survival time. Comparison between the subgroup of group A that had one NCF and the subgroup that had two or more NCFs revealed MSTs of 700 days and 180 days, respectively, with a significantly longer MST among the patients with one NCF (
P
= 0.0021). In addition, no difference from the MST of 333 days in group C was seen among the group A patients with two or more NCFs.
Conclusion
The postoperative survival time of patients with one NCF was prolonged by the advent of NACA, but no significant prolongation was observed in the patients with two or more NCFs. |
| doi_str_mv | 10.1007/s10147-008-0841-8 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67475601</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1784098231</sourcerecordid><originalsourceid>FETCH-LOGICAL-c405t-58f75aa42aeefa5d0e329cf0e75cfc88cadab1d7ee6cf824eb2b2d62bc766c493</originalsourceid><addsrcrecordid>eNqFkU1vFSEUhomxsbX6A9wY4sIdFhgGmKVp6kfSxEV1TRg4jDQzwxWYa_rvy_XepImJcQWB531P4EHoDaMfGKXqqjDKhCKUakK1YEQ_QxdMdIoopfjztu_a4SB5f45elnJPKVOy5y_QORv6oZNMXKD9XZzWGKKzqwOcAt6neVuAZPCbqzGtuGx5gvyAQ8o42Eys3x9Yjydbao4O_4lm7Lcc1wnXDLYusFb8O9afeE17mLFdazxhdmp35RU6C3Yu8Pq0XqIfn26-X38ht98-f73-eEucoH0lvQ6qt1ZwCxBs7yl0fHCBgupdcFo76-3IvAKQLmguYOQj95KPTknpxNBdovfH3l1OvzYo1SyxOJhnu0LaipFKqF5S9l-QU04FG0QD3_0F3qctr-0Rjen0MGjdNYgdIZdTKRmC2eW42PxgGDUHdeaozjR15qDO6JZ5eyrexgX8U-LkqgH8CJTd4achP03-d-sjBrmnHg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>203899883</pqid></control><display><type>article</type><title>Significance of volume-reduction surgery for far-advanced gastric cancer during treatment with novel anticancer agents</title><source>Springer Nature</source><creator>Yamamoto, Yuji ; Yoshikawa, Takaki ; Morinaga, Souichirou ; Kasahara, Akira ; Yoneyama, Katsuya ; Osaragi, Tomohiko ; Matsuura, Hitoshi ; Yoshida, Tatsuya ; Hasegawa, Shinichi</creator><creatorcontrib>Yamamoto, Yuji ; Yoshikawa, Takaki ; Morinaga, Souichirou ; Kasahara, Akira ; Yoneyama, Katsuya ; Osaragi, Tomohiko ; Matsuura, Hitoshi ; Yoshida, Tatsuya ; Hasegawa, Shinichi</creatorcontrib><description>Background
We retrospectively assessed the survival benefit of novel anticancer agents (NACA) after volume-reduction surgery for far-advanced gastric cancer (FAGC).
Methods
From 1995 to 2005, 41 patients with FAGC underwent chemotherapy after volume-reduction surgery. Those treated since 2000 who received NACA were referred to as group A, and those treated before 2000, who received anticancer agents other than NACA, were referred to as group B. In addition, 21 patients with unresectable gastric cancer treated since 2000 who received NACA were referred to as group C. We investigated the significance of volume-reduction surgery during treatment with NACA.
Results
The median survival time (MST) was significantly prolonged in group A (626 days) compared to group B (364 days;
P
= 0.0156). Multivariate analysis showed that having one noncurative factor (NCF), and the use of NACA, were factors that contributed to survival time. Comparison between the subgroup of group A that had one NCF and the subgroup that had two or more NCFs revealed MSTs of 700 days and 180 days, respectively, with a significantly longer MST among the patients with one NCF (
P
= 0.0021). In addition, no difference from the MST of 333 days in group C was seen among the group A patients with two or more NCFs.
Conclusion
The postoperative survival time of patients with one NCF was prolonged by the advent of NACA, but no significant prolongation was observed in the patients with two or more NCFs.</description><identifier>ISSN: 1341-9625</identifier><identifier>EISSN: 1437-7772</identifier><identifier>DOI: 10.1007/s10147-008-0841-8</identifier><identifier>PMID: 19593614</identifier><language>eng</language><publisher>Japan: Springer Japan</publisher><subject>Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Cancer Research ; Cancer surgery ; Chemotherapy ; Combined Modality Therapy ; Female ; Humans ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Multivariate Analysis ; Oncology ; Original Article ; Retrospective Studies ; Stomach ; Stomach Neoplasms - drug therapy ; Stomach Neoplasms - mortality ; Stomach Neoplasms - surgery ; Surgical Oncology</subject><ispartof>International journal of clinical oncology, 2009-06, Vol.14 (3), p.225-229</ispartof><rights>Japan Society of Clinical Oncology 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c405t-58f75aa42aeefa5d0e329cf0e75cfc88cadab1d7ee6cf824eb2b2d62bc766c493</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19593614$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yamamoto, Yuji</creatorcontrib><creatorcontrib>Yoshikawa, Takaki</creatorcontrib><creatorcontrib>Morinaga, Souichirou</creatorcontrib><creatorcontrib>Kasahara, Akira</creatorcontrib><creatorcontrib>Yoneyama, Katsuya</creatorcontrib><creatorcontrib>Osaragi, Tomohiko</creatorcontrib><creatorcontrib>Matsuura, Hitoshi</creatorcontrib><creatorcontrib>Yoshida, Tatsuya</creatorcontrib><creatorcontrib>Hasegawa, Shinichi</creatorcontrib><title>Significance of volume-reduction surgery for far-advanced gastric cancer during treatment with novel anticancer agents</title><title>International journal of clinical oncology</title><addtitle>Int J Clin Oncol</addtitle><addtitle>Int J Clin Oncol</addtitle><description>Background
We retrospectively assessed the survival benefit of novel anticancer agents (NACA) after volume-reduction surgery for far-advanced gastric cancer (FAGC).
Methods
From 1995 to 2005, 41 patients with FAGC underwent chemotherapy after volume-reduction surgery. Those treated since 2000 who received NACA were referred to as group A, and those treated before 2000, who received anticancer agents other than NACA, were referred to as group B. In addition, 21 patients with unresectable gastric cancer treated since 2000 who received NACA were referred to as group C. We investigated the significance of volume-reduction surgery during treatment with NACA.
Results
The median survival time (MST) was significantly prolonged in group A (626 days) compared to group B (364 days;
P
= 0.0156). Multivariate analysis showed that having one noncurative factor (NCF), and the use of NACA, were factors that contributed to survival time. Comparison between the subgroup of group A that had one NCF and the subgroup that had two or more NCFs revealed MSTs of 700 days and 180 days, respectively, with a significantly longer MST among the patients with one NCF (
P
= 0.0021). In addition, no difference from the MST of 333 days in group C was seen among the group A patients with two or more NCFs.
Conclusion
The postoperative survival time of patients with one NCF was prolonged by the advent of NACA, but no significant prolongation was observed in the patients with two or more NCFs.</description><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Cancer Research</subject><subject>Cancer surgery</subject><subject>Chemotherapy</subject><subject>Combined Modality Therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Retrospective Studies</subject><subject>Stomach</subject><subject>Stomach Neoplasms - drug therapy</subject><subject>Stomach Neoplasms - mortality</subject><subject>Stomach Neoplasms - surgery</subject><subject>Surgical Oncology</subject><issn>1341-9625</issn><issn>1437-7772</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNqFkU1vFSEUhomxsbX6A9wY4sIdFhgGmKVp6kfSxEV1TRg4jDQzwxWYa_rvy_XepImJcQWB531P4EHoDaMfGKXqqjDKhCKUakK1YEQ_QxdMdIoopfjztu_a4SB5f45elnJPKVOy5y_QORv6oZNMXKD9XZzWGKKzqwOcAt6neVuAZPCbqzGtuGx5gvyAQ8o42Eys3x9Yjydbao4O_4lm7Lcc1wnXDLYusFb8O9afeE17mLFdazxhdmp35RU6C3Yu8Pq0XqIfn26-X38ht98-f73-eEucoH0lvQ6qt1ZwCxBs7yl0fHCBgupdcFo76-3IvAKQLmguYOQj95KPTknpxNBdovfH3l1OvzYo1SyxOJhnu0LaipFKqF5S9l-QU04FG0QD3_0F3qctr-0Rjen0MGjdNYgdIZdTKRmC2eW42PxgGDUHdeaozjR15qDO6JZ5eyrexgX8U-LkqgH8CJTd4achP03-d-sjBrmnHg</recordid><startdate>20090601</startdate><enddate>20090601</enddate><creator>Yamamoto, Yuji</creator><creator>Yoshikawa, Takaki</creator><creator>Morinaga, Souichirou</creator><creator>Kasahara, Akira</creator><creator>Yoneyama, Katsuya</creator><creator>Osaragi, Tomohiko</creator><creator>Matsuura, Hitoshi</creator><creator>Yoshida, Tatsuya</creator><creator>Hasegawa, Shinichi</creator><general>Springer Japan</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20090601</creationdate><title>Significance of volume-reduction surgery for far-advanced gastric cancer during treatment with novel anticancer agents</title><author>Yamamoto, Yuji ; Yoshikawa, Takaki ; Morinaga, Souichirou ; Kasahara, Akira ; Yoneyama, Katsuya ; Osaragi, Tomohiko ; Matsuura, Hitoshi ; Yoshida, Tatsuya ; Hasegawa, Shinichi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c405t-58f75aa42aeefa5d0e329cf0e75cfc88cadab1d7ee6cf824eb2b2d62bc766c493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Cancer Research</topic><topic>Cancer surgery</topic><topic>Chemotherapy</topic><topic>Combined Modality Therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Retrospective Studies</topic><topic>Stomach</topic><topic>Stomach Neoplasms - drug therapy</topic><topic>Stomach Neoplasms - mortality</topic><topic>Stomach Neoplasms - surgery</topic><topic>Surgical Oncology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yamamoto, Yuji</creatorcontrib><creatorcontrib>Yoshikawa, Takaki</creatorcontrib><creatorcontrib>Morinaga, Souichirou</creatorcontrib><creatorcontrib>Kasahara, Akira</creatorcontrib><creatorcontrib>Yoneyama, Katsuya</creatorcontrib><creatorcontrib>Osaragi, Tomohiko</creatorcontrib><creatorcontrib>Matsuura, Hitoshi</creatorcontrib><creatorcontrib>Yoshida, Tatsuya</creatorcontrib><creatorcontrib>Hasegawa, Shinichi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yamamoto, Yuji</au><au>Yoshikawa, Takaki</au><au>Morinaga, Souichirou</au><au>Kasahara, Akira</au><au>Yoneyama, Katsuya</au><au>Osaragi, Tomohiko</au><au>Matsuura, Hitoshi</au><au>Yoshida, Tatsuya</au><au>Hasegawa, Shinichi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Significance of volume-reduction surgery for far-advanced gastric cancer during treatment with novel anticancer agents</atitle><jtitle>International journal of clinical oncology</jtitle><stitle>Int J Clin Oncol</stitle><addtitle>Int J Clin Oncol</addtitle><date>2009-06-01</date><risdate>2009</risdate><volume>14</volume><issue>3</issue><spage>225</spage><epage>229</epage><pages>225-229</pages><issn>1341-9625</issn><eissn>1437-7772</eissn><abstract>Background
We retrospectively assessed the survival benefit of novel anticancer agents (NACA) after volume-reduction surgery for far-advanced gastric cancer (FAGC).
Methods
From 1995 to 2005, 41 patients with FAGC underwent chemotherapy after volume-reduction surgery. Those treated since 2000 who received NACA were referred to as group A, and those treated before 2000, who received anticancer agents other than NACA, were referred to as group B. In addition, 21 patients with unresectable gastric cancer treated since 2000 who received NACA were referred to as group C. We investigated the significance of volume-reduction surgery during treatment with NACA.
Results
The median survival time (MST) was significantly prolonged in group A (626 days) compared to group B (364 days;
P
= 0.0156). Multivariate analysis showed that having one noncurative factor (NCF), and the use of NACA, were factors that contributed to survival time. Comparison between the subgroup of group A that had one NCF and the subgroup that had two or more NCFs revealed MSTs of 700 days and 180 days, respectively, with a significantly longer MST among the patients with one NCF (
P
= 0.0021). In addition, no difference from the MST of 333 days in group C was seen among the group A patients with two or more NCFs.
Conclusion
The postoperative survival time of patients with one NCF was prolonged by the advent of NACA, but no significant prolongation was observed in the patients with two or more NCFs.</abstract><cop>Japan</cop><pub>Springer Japan</pub><pmid>19593614</pmid><doi>10.1007/s10147-008-0841-8</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1341-9625 |
| ispartof | International journal of clinical oncology, 2009-06, Vol.14 (3), p.225-229 |
| issn | 1341-9625 1437-7772 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67475601 |
| source | Springer Nature |
| subjects | Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer Research Cancer surgery Chemotherapy Combined Modality Therapy Female Humans Male Medicine Medicine & Public Health Middle Aged Multivariate Analysis Oncology Original Article Retrospective Studies Stomach Stomach Neoplasms - drug therapy Stomach Neoplasms - mortality Stomach Neoplasms - surgery Surgical Oncology |
| title | Significance of volume-reduction surgery for far-advanced gastric cancer during treatment with novel anticancer agents |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T13%3A37%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Significance%20of%20volume-reduction%20surgery%20for%20far-advanced%20gastric%20cancer%20during%20treatment%20with%20novel%20anticancer%20agents&rft.jtitle=International%20journal%20of%20clinical%20oncology&rft.au=Yamamoto,%20Yuji&rft.date=2009-06-01&rft.volume=14&rft.issue=3&rft.spage=225&rft.epage=229&rft.pages=225-229&rft.issn=1341-9625&rft.eissn=1437-7772&rft_id=info:doi/10.1007/s10147-008-0841-8&rft_dat=%3Cproquest_cross%3E1784098231%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c405t-58f75aa42aeefa5d0e329cf0e75cfc88cadab1d7ee6cf824eb2b2d62bc766c493%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=203899883&rft_id=info:pmid/19593614&rfr_iscdi=true |